| Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis KR Broglio, M Quintana, M Foster, M Olinger, A McGlothlin, SM Berry, ... JAMA oncology 2 (6), 751-760, 2016 | 312 | 2016 |
| The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model RJ Bateman, TL Benzinger, S Berry, DB Clifford, C Duggan, AM Fagan, ... Alzheimer's & Dementia 13 (1), 8-19, 2017 | 270 | 2017 |
| Effect of P2Y12 inhibitors on survival free of organ support among non–critically ill hospitalized patients with COVID-19: a randomized clinical trial JS Berger, LZ Kornblith, MN Gong, HR Reynolds, M Cushman, Y Cheng, ... Jama 327 (3), 227-236, 2022 | 102 | 2022 |
| Bayesian model search and multilevel inference for SNP association studies MA Wilson, ES Iversen, MA Clyde, SC Schmidler, JM Schildkraut The annals of applied statistics 4 (3), 1342, 2010 | 83 | 2010 |
| Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer JM Schildkraut, ES Iversen, MA Wilson, MA Clyde, PG Moorman, ... PLoS One 5 (4), e10061, 2010 | 82 | 2010 |
| Bayesian analysis: using prior information to interpret the results of clinical trials M Quintana, K Viele, RJ Lewis Jama 318 (16), 1605-1606, 2017 | 74 | 2017 |
| Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development S Paganoni, JD Berry, M Quintana, E Macklin, BR Saville, MA Detry, ... Annals of neurology 91 (2), 165-175, 2022 | 50 | 2022 |
| Incorporating model uncertainty in detecting rare variants: the Bayesian risk index MA Quintana, JL Berstein, DC Thomas, DV Conti Genetic epidemiology 35 (7), 638-649, 2011 | 47 | 2011 |
| Temporal order of clinical and biomarker changes in familial frontotemporal dementia AM Staffaroni, M Quintana, B Wendelberger, HW Heuer, LL Russell, ... Nature medicine 28 (10), 2194-2206, 2022 | 41 | 2022 |
| Integrative variable selection via Bayesian model uncertainty MA Quintana, DV Conti Statistics in medicine 32 (28), 4938-4953, 2013 | 41 | 2013 |
| DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network (2017) The DIAN-TU next generation Alzheimer’s prevention trial: adaptive design and disease … RJ Bateman, TL Benzinger, S Berry, DB Clifford, C Duggan, AM Fagan, ... Alzheimers Dement 13, 8-19, 0 | 38 | |
| A novel cognitive disease progression model for clinical trials in autosomal‐dominant Alzheimer's disease G Wang, S Berry, C Xiong, J Hassenstab, M Quintana, EM McDade, ... Statistics in medicine 37 (21), 3047-3055, 2018 | 34 | 2018 |
| Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study N Carrillo, MC Malicdan, P Leoyklang, JA Shrader, G Joe, C Slota, ... Genetics in medicine 23 (11), 2067-2075, 2021 | 32 | 2021 |
| Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot BJ Gajewski, SM Berry, M Quintana, M Pasnoor, M Dimachkie, L Herbelin, ... Statistics in medicine 34 (7), 1134-1149, 2015 | 30 | 2015 |
| A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization AR Brown, BJ Gajewski, LS Aaronson, DP Mudaranthakam, SL Hunt, ... Trials 17, 1-9, 2016 | 25 | 2016 |
| Bayesian model of disease progression in GNE myopathy M Quintana, J Shrader, C Slota, G Joe, JC McKew, M Fitzgerald, WA Gahl, ... Statistics in Medicine 38 (8), 1459-1474, 2019 | 23 | 2019 |
| Value-generating exploratory trials in neurodegenerative dementias LG Friedman, N McKeehan, Y Hara, JL Cummings, DC Matthews, J Zhu, ... Neurology 96 (20), 944-954, 2021 | 22 | 2021 |
| Incorporating prior biologic information for high-dimensional rare variant association studies MA Quintana, FR Schumacher, G Casey, JL Bernstein, L Li, DV Conti Human heredity 74 (3-4), 184-195, 2013 | 20 | 2013 |
| Polymorphism in the IL18 Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women RT Palmieri, MA Wilson, ES Iversen, MA Clyde, B Calingaert, ... Cancer Epidemiology Biomarkers & Prevention 17 (12), 3567-3572, 2008 | 20 | 2008 |
| Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult-to-treat Japanese patients chronically infected with hepatitis C genotype 1b P McEwan, T Ward, S Webster, Y Yuan, A Kalsekar, K Broglio, I Kamae, ... Value in Health Regional Issues 3, 136-145, 2014 | 18 | 2014 |
